| Ophthotech-Not Recruiting |
 |
 |
 Share
This injectable therapy (E10030) is currently in a Phase 2b trial with 445 patients with wet macular degeneration. It compares outcomes between patient groups receiving standard Lucentis treatment and those receiving Lucentis and E10030. Lucentis blocks the substance called VEGF, which promotes the growth of blood vessels. E10030 blocks a different substance, PDGF, that seems to contribute to wet AMD as well. The goal is to show that the combined therapy provides better results. Results of the trial will be released in the first half of 2012. For more information, visit Clinical Trials.gov or Ophthotech.
|
Search
Get News!
SIGN UP NOW
To receive the "AMD Update" and keep up-to-date with the latest research & treatment options:
For Email Newsletters you can trust